Cheng Ran

Organic Chemistry, Medicinal Chemistry, Protac, Molecular Glues

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in cyclin-dependent kinase inhibitors in cancer, here's a comprehensive review discussing their progression beyond CDK4/6 inhibitors for breast cancer https://t.co/jAQnkSQcVO
https://t.co/39JOxXgD1a

#ASCO26

[Chinese Chemical Society (CCS) @ChineseChemSoc]

.@CCSChemistry Article Highlight: Photocatalytic triple defluorination-driven [1+2+3] lactone conversion: A rapid method for constructing δ-lactones from trifluoromethylstyrene

Click to read: https://t.co/DmWItYoqqu

#chemistry #openaccess #science #chemtwitter

[Yijun Xiong @Xiong1jun]

Excited to share my PhD work in the Cravatt lab at @scrippsresearch, now published in @J_A_C_S! We show how comparing acrylamide and butynamide probes expands the ligandable proteome, uncovering targets including ACTMAP. Huge thanks to Ben and co-authors https://t.co/A9n3aYiAnH

[drug hunter @drughunter_com]

TNG961: An HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers

Presented by Hilary Nicholson of Tango Therapeutics at the AACR Annual Meeting 2026 New Drugs on the Horizon session, TNG961 is a potential first-in-class CRBN-mediated molecular glue degrader of HBS1L for FOCAD-deleted cancers, a subset of chr9p21-deleted tumors.

FOCAD loss impairs SKI complex–mediated mRNA quality control, creating dependence on the HBS1L/PELO ribosome-rescue pathway. By selectively degrading HBS1L while sparing the closely related CRBN neosubstrate GSPT1, TNG961 disrupts this compensatory pathway and triggers translational stress in FOCAD-negative cells.

Preclinically, TNG961 shows ~100-fold selectivity for FOCAD-deleted vs. WT cells and induces tumor regressions in pancreatic and NSCLC xenograft models, including tumors progressing on PRMT5 inhibitor treatment.

Read more: https://t.co/s44pN0QppZ

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The ovarian cancer drug market
https://t.co/Fj7xf8ekXY

This new article analyses the pipeline of drugs in development for ovarian cancer, such as antibody-drug conjugates, and their expected impact on the market